ARTICLE | Financial News
SCM raises $35M series C for stem cells to treat inflammation
September 7, 2018 12:28 PM UTC
SCM Lifescience (Incheon, South Korea) closed a $35 million series C round from 15 investors last Friday to advance its pipeline of disease-specific mesenchymal stem cell therapies.
Seoul-based investors DS Asset Management and Neoplux contributed the most to the round at $4.5 million apiece...